Please login to the form below

Not currently logged in
Email:
Password:

Affymax

This page shows the latest Affymax news and features for those working in and with pharma, biotech and healthcare.

Omontys terminal as Takeda switches off support

Omontys terminal as Takeda switches off support

Omontys terminal as Takeda switches off support. Japanese company ends anaemia treatment partnership with Affymax. ... Takeda confirmed today it was ending its partnership with Affymax over troubled anaemia treatment Omontys, which was linked to several

Latest news

  • Takeda pipeline hit by fasiglifam failure Takeda pipeline hit by fasiglifam failure

    Furthermore, earlier this year the company withdrew its marketing authorization application (MAA) in Europe for the Affymax-partnered anaemia treatment Omontys (peginesatide) and recalled all lots of the drug in the

  • Affymax in a tailspin after Omontys recall Affymax in a tailspin after Omontys recall

    Affymax in a tailspin after Omontys recall. Makes heavy job cuts in face of bankruptcy threat. ... Affymax is slashing three quarters of its workforce and could be facing bankruptcy in the wake of the recall last month of kidney disease drug Omontys, its

  • Takeda-Affymax recall Omontys in US after deaths Takeda-Affymax recall Omontys in US after deaths

    Takeda-Affymax recall Omontys in US after deaths. Severe allergic reactions reported in kidney disease patients taking anaemia drug. ... The recall is voluntary at the moment, with Takeda and Affymax working with the US FDA.

  • Amgen buoyant as profits rise in Q3 Amgen buoyant as profits rise in Q3

    switch to newer drugs such as Takeda/Affymax' Omontys (peginasetide), which was approved in the US earlier this year.

  • FDA clears Affymax' anaemia drug Omontys

    FDA clears Affymax' anaemia drug Omontys. Will be co-marketed by Takeda for use in patients with chronic kidney disease. ... The US FDA has approved Omontys, a new treatment developed by Affymax for anaemia in patients on dialysis.

More from news
Approximately 3 fully matching, plus 5 partially matching documents found.

Latest appointments

  • KaloBios names Herb Cross as CFO KaloBios names Herb Cross as CFO

    KaloBios names Herb Cross as CFO. He joins from Affymax. Herb Cross is to join KaloBios as the company's new chief financial officer. ... Cross joins from biopharma company Affymax, where he was also chief financial officer.

  • CytomX makes senior changes following Pfizer deal CytomX makes senior changes following Pfizer deal

    During his time at Affymax, Dr Polu headed several areas, including clinical sciences, clinical operations and drug safety/pharmacovigilance. ... Prior to this period at Affymax, Dr Polu was executive director, global development at Amgen, where he

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics